WALTHAM, Mass. — September 9, 2026
Revvity, Inc. announced that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to strengthen Revvity’s position in human-relevant life sciences tools for next-generation metabolic drug discovery, particularly research involving GLP-1 and GPCR-targeting therapies. By combining HCD’s human pancreatic beta cell models with Revvity’s existing capabilities in cell analysis, detection, high-content screening, automation and gene editing, the transaction is designed to provide researchers with more integrated solutions spanning early discovery and preclinical development. The acquisition is expected to close in Q4 2026, subject to customary closing conditions and required regulatory approvals, with financial terms not disclosed.
HCD Adds Human Pancreatic Beta Cell Models
Human Cell Design’s flagship EndoC-βH5 human pancreatic beta cell model will become a key addition to Revvity’s Life Sciences portfolio, providing researchers with a human-relevant system for studying beta cell physiology and function in diabetes and obesity research. HCD also brings specialized media and reagents, preclinical research capabilities and its proprietary NatLine cell-line development platform, which supports the creation of functionally consistent human cell models. The addition is particularly relevant as pharmaceutical researchers seek more physiologically representative systems for evaluating emerging metabolic therapies. For Revvity, integrating HCD’s models with its established technologies could strengthen its ability to support drug discovery programs that require detailed cellular readouts while helping customers move from experimental biology toward increasingly translational research applications.
Revvity Integrates Screening and Detection Technologies
The acquisition creates an opportunity to combine HCD’s cellular models with Revvity’s broad portfolio of detection, screening and analysis technologies, including HTRF™, AlphaLISA™, pHSense™ and ATPlite™ assays. These technologies can support measurements such as cAMP signaling, insulin responses, receptor internalization, cell viability and proliferation. Revvity also expects HCD’s models to complement its high-content screening capabilities, allowing researchers to analyze increasingly complex cellular phenotypes within drug discovery workflows. The company highlighted the growing importance of wet-lab validation as artificial intelligence becomes more integrated into scientific research, with human-relevant cell models providing an experimental foundation for testing AI-generated hypotheses. The combined capabilities could therefore position Revvity to offer a more comprehensive workflow for customers developing metabolic disease therapies, particularly programs requiring human-relevant biological validation before advancing toward clinical development.
Advertisement
Revvity Targets Research-to-Clinic Expansion
Beyond early-stage drug discovery, the HCD acquisition expands Revvity’s potential reach into regenerative medicine and later-stage cell-based applications. HCD’s technology can support research into regenerative approaches for Type 1 diabetes, as well as quality-control activities associated with cell-based therapies progressing toward commercialization. This broader application aligns with Revvity’s strategy of supporting customers across the research-to-clinic continuum rather than focusing exclusively on discovery-stage tools. Following completion of the transaction, the combined portfolio is expected to provide pharmaceutical, biotechnology and research customers with access to human cell models alongside detection, screening and analytical technologies. The acquisition of Human Cell Design therefore strengthens Revvity’s metabolic disease capabilities while expanding its broader life sciences platform into increasingly human-relevant research, translational development and regenerative medicine applications.
Source: Revvity, ,press release
